Bicarbonate

Bicarbonate

SCHEMBL3688947

O=C(O)O.O=S(=O)(O)OS(=O)(=O)O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.44
TSHR P16473 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
CA5A P35218 2/20 0.36
CA5B Q9Y2D0 2/20 0.36
ALDH1A1 P00352 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
NT5E P21589 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31
CA7 P43166 1/20 0.31
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3781 0.88
SCHEMBL56331 0.88 CA2 (0.54) CA2TSHRTDP1CA1CA9
Benzene SCHEMBL9320024 0.85 CA2 (0.44) CA2TSHRTDP1CA1CA9
Sulfuric Acid SCHEMBL560688 0.84 CA5A (0.55) CA2TSHRTDP1CA1CA9
Water SCHEMBL2456364 0.84 CA2 (0.50) CA2TSHRTDP1CA1CA9
Water SCHEMBL10934974 0.84 CA2 (0.50) CA2TSHRTDP1CA1CA9
Phosphine SCHEMBL10457030 0.84 CA2 (0.50) CA2TSHRTDP1CA1CA9
Methane SCHEMBL7363776 0.84 CA2 (0.50) CA2TSHRTDP1CA1CA9
SCHEMBL10495537 0.84 CA2 (0.50) CA2TSHRTDP1CA1CA9
SCHEMBL337658 0.84 CA2 (0.50) CA2TSHRTDP1CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143473-A1 COMBINATION TREATMENT WITH STRONTIUM FOR THE PROPHYLAXIS AND/OR TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS OSTEOLOGIX A/S 2010-06-10 US claimed
US-20060275503-A1 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions NORDIC BONE A/S (DK) 2006-12-07 US claimed
EP-1622630-A2 STRONTIUM COMBINATIONS FOR THE PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS Osteologix A/S (DK) 2006-02-08 EP claimed
WO-2004098618-A2 STRONTIUM COMBINATIONS FOR PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS OSTEOLOGIX A/S (DK) 2004-11-18 WO claimed
CN-103534250-B Be used for the treatment of the substituted indole derivatives of dysimmunity Switzerland Novartis Animal Health Co.,Ltd. (CH) 2016-05-11 CN disclosed
US-8623422-B2 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions OSTEOLOGIX A/S (DK) 2014-01-07 US disclosed
EP-2266584-A2 Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions Osteologix A/S (DK) 2010-12-29 EP disclosed
US-20100143473-A1 COMBINATION TREATMENT WITH STRONTIUM FOR THE PROPHYLAXIS AND/OR TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS OSTEOLOGIX A/S 2010-06-10 US disclosed
US-20060275503-A1 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions NORDIC BONE A/S (DK) 2006-12-07 US disclosed